IP Library Granted Patent US 8,071,704
Granted Patent B2
US 8,071,704 · App. 12/241,102 · Granted Dec 6, 2011

Prepolymerizable surface active monomers with both fluorine-containing groups and hydrophilic groups

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,704
App. No.
12/241,102
Granted
Dec 6, 2011
Kind
B2
Abstract

Provided are surface modified contact lenses formed from one or more fumaric- or itaconic-containing prepolymers having reactive functionality that is complimentary to surface modifying polymers.

Claims (18)

1. A reactive surface active monomer having the structure below:

2. A polymerizable monomer mixture comprising at least one monomer of claim 1 .

3. The polymerizable monomer mixture of claim 2 wherein a relative weight % of the polymerizable surface active monomer as compared to the total monomer mix weight % is from about 0.01% to about 10%.

4. The polymerizable monomer mixture of claim 2 wherein a relative weight % of the polymerizable surface active monomer as compared to the total monomer mix weight % is about 0.1% to about 5%.

5. The polymerizable monomer mixture of claim 2 wherein a relative weight % of the polymerizable surface active monomer as compared to the total monomer mix weight % is about 0.2% to about 1%.

6. The monomer mixture of claim 2 further comprising at least one hydrophilic monomer.

7. The monomer mixture of claim 6 wherein the hydrophilic monomer is selected from the group consisting of ethylenically unsaturated lactam-containing monomers, methacrylic acids, acrylic acids, (meth)acrylic substituted alcohols, (meth)acrylamides, vinyl carbonate, vinyl carbamate monomers, oxazolinone monomers, glycerol methacrylate, polyethyleneglycol monomethacrylate and mixtures thereof.

8. The monomer mixture of claim 2 further comprising at least one silicone monomer.

9. The monomer mixture of claim 8 wherein the at least one silicone monomer is a bulky polysiloxanylalkyl (meth)acrylic monomer.

10. The monomer mixture of claim 8 wherein the at least one silicone monomer is selected from the group consisting of methacryloxypropyl tris(trimethylsiloxy)silane (TRIS), pentamethyldisiloxanylmethylmethacrylate, tris(trimethylsiloxy)methacryloxy propylsilane, phenyltetramethyldisiloxanylethyl acrylate, methylbis(trimethylsiloxy)methacryloxymethyl silane and mixtures thereof.

11. The monomer mixture of claim 2 further comprising a crosslinking agent.

12. A surface modified medical device comprising a medical device manufactured from a monomer having the structure below:

13. The medical device of claim 12 wherein the medical device has at least one of the property selected from the group consisting of oxygen permeability, hydrolytically stability, biologically inertness, and transparency.

14. The medical device of claim 12 wherein the medical device has a three-dimensional networks which permits the transport of oxygen.

15. The medical device of claim 12 wherein the medical device is an optically clear, strong and hydrophilic medical device.

16. The medical device of claim 15 wherein the medical device is an ophthalmic lens.

17. The medical device of claim 16 wherein the medical device is a contact lens.

18. The medical device of claim 16 wherein the medical device is an intraocular lens.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Apr 23, 2012
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
Reel/Frame 028090/0019 →